CA-TSG-CONSUMER-PARTNERS
25.3.2019 12:01:06 CET | Business Wire | Press release
TSG Consumer Partners (“TSG”), a leading private equity firm focused exclusively on the branded consumer sector, today announced that it has opened an office in London, its first office outside the U.S.
TSG’s presence in London deepens its commitment to the European market and enhances the firm’s ability to identify and execute on compelling investment opportunities in the region. TSG’s foothold in Europe comes following a series of investments in leading European companies such as Revolution Beauty – which was recently named the third fastest growing private company by the Sunday Times Fast Track 100 – BrewDog, Canyon Bicycles, Bergfreunde.de, as well as ZOEVA and HUDA Beauty, both of which opened offices in London last year.
Beth Pickens, former Managing Director and head of European consumer banking at William Blair, has joined TSG as a Principal based in London. Colin Welch, Partner and Managing Director at TSG, is responsible for guiding the new office located in Mayfair.
“Europe represents a dynamic and attractive marketplace with exciting investment opportunities across the consumer and retail spectrum,” said Chuck Esserman, CEO and Founder of TSG Consumer Partners. “TSG has a strong track record in Europe, and the size of our business has grown steadily over the past few years – one-third of the capital from our TSG7 fund was deployed overseas, primarily on the continent. Now with an established office in London, we will be better positioned to collaborate closely with leading brands and their management teams to help them reach their full global potential.”
Colin Welch commented, “The addition of a London office further positions us as the partner of choice for consumer companies throughout Europe, particularly those looking to capitalize on cross border growth opportunities. It also helps us create additional value for our U.S.-based partner companies as they expand their overseas operations. I am thrilled to work closely with Beth, as we collaborate to identify new investment opportunities and accelerate our momentum in the region.”
Beth Pickens added, “TSG is the pre-eminent investor in the consumer sector and their collaborative approach, and appreciation of the power of an entrepreneur’s vision, makes the firm truly unique. I’m excited to be joining Colin and the talented team at TSG, as we deepen TSG’s European presence and continue to back the global growth of strong consumer brands.”
Beth Pickens joins TSG with nearly two decades of investment banking experience, most recently as Managing Director and head of European consumer banking at William Blair in London. In addition to providing strategic and financial advice to companies across the consumer sector, Ms. Pickens founded William Blair’s European consumer practice, and has been based in London since 2001. Her notable engagements include advising Rapha Racing Limited on its sale to RZC Investments, Happy Socks AB on its sale to Palamon Capital Partners and the initial public offering and follow-on offerings for Tumi.
Ms. Pickens received a Master of Business Administration from the University of Chicago Graduate School of Business, and a Bachelor of Science in Finance from the University of Illinois.
About TSG Consumer Partners
TSG Consumer Partners, LLC is a leading private equity firm focused exclusively on the branded consumer sector. Since its founding in 1987, TSG has been an active investor in the food, beverage, restaurant, beauty, personal care, fitness, health & wellness, household, apparel & accessories, and e-commerce sectors. Representative past and present partner companies include Duckhorn Wine Company, Planet Fitness, IT Cosmetics, REVOLVE, HUDA Beauty, BrewDog, Canyon Bicycles, Pabst, Backcountry, vitaminwater, thinkThin, popchips, Stumptown, Smashbox Cosmetics and e.l.f. Cosmetics. For more information, visit tsgconsumer.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190325005254/en/
Contact:
TSG Consumer Partners Sard Verbinnen & Co Conrad Harrington / Dan Goldstein / Julie Rudnick +44 20 7467 1050 / 310-201-2040 / 212-687-8080
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
